Cerus Corporation

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, ABT has a market cap of 195.3B. Regarding current trading prices, CERS is priced at $2.32, while ABT trades at $114.51.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas ABT's P/E ratio is 30.16. In terms of profitability, CERS's ROE is -0.28%, compared to ABT's ROE of +0.13%. Regarding short-term risk, CERS is more volatile compared to ABT. This indicates potentially higher risk in terms of short-term price fluctuations for CERS.Check ABT's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, CERS is priced at $2.32, while BSX-PA trades at $122.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, CERS's ROE is -0.28%, compared to BSX-PA's ROE of +0.13%. Regarding short-term risk, CERS is more volatile compared to BSX-PA. This indicates potentially higher risk in terms of short-term price fluctuations for CERS.Check BSX-PA's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, SYK has a market cap of 145.5B. Regarding current trading prices, CERS is priced at $2.32, while SYK trades at $383.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas SYK's P/E ratio is 45.15. In terms of profitability, CERS's ROE is -0.28%, compared to SYK's ROE of +0.15%. Regarding short-term risk, CERS is more volatile compared to SYK. This indicates potentially higher risk in terms of short-term price fluctuations for CERS.Check SYK's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, MDT has a market cap of 124.3B. Regarding current trading prices, CERS is priced at $2.32, while MDT trades at $98.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas MDT's P/E ratio is 26.47. In terms of profitability, CERS's ROE is -0.28%, compared to MDT's ROE of +0.13%. Regarding short-term risk, CERS is more volatile compared to MDT. This indicates potentially higher risk in terms of short-term price fluctuations for CERS.Check MDT's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, BSX has a market cap of 110.6B. Regarding current trading prices, CERS is priced at $2.32, while BSX trades at $74.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas BSX's P/E ratio is 38.43. In terms of profitability, CERS's ROE is -0.28%, compared to BSX's ROE of +0.13%. Regarding short-term risk, CERS is more volatile compared to BSX. This indicates potentially higher risk in terms of short-term price fluctuations for CERS.Check BSX's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, EW has a market cap of 46.8B. Regarding current trading prices, CERS is priced at $2.32, while EW trades at $81.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas EW's P/E ratio is 44.08. In terms of profitability, CERS's ROE is -0.28%, compared to EW's ROE of +0.10%. Regarding short-term risk, CERS is more volatile compared to EW. This indicates potentially higher risk in terms of short-term price fluctuations for CERS.Check EW's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, BRKRP has a market cap of 45.8B. Regarding current trading prices, CERS is priced at $2.32, while BRKRP trades at $308.48.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas BRKRP's P/E ratio is N/A. In terms of profitability, CERS's ROE is -0.28%, compared to BRKRP's ROE of -0.00%. Regarding short-term risk, CERS is more volatile compared to BRKRP. This indicates potentially higher risk in terms of short-term price fluctuations for CERS.Check BRKRP's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, PHG has a market cap of 30B. Regarding current trading prices, CERS is priced at $2.32, while PHG trades at $31.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas PHG's P/E ratio is 27.65. In terms of profitability, CERS's ROE is -0.28%, compared to PHG's ROE of +0.08%. Regarding short-term risk, CERS is more volatile compared to PHG. This indicates potentially higher risk in terms of short-term price fluctuations for CERS.Check PHG's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, DXCM has a market cap of 28.5B. Regarding current trading prices, CERS is priced at $2.32, while DXCM trades at $74.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas DXCM's P/E ratio is 34.97. In terms of profitability, CERS's ROE is -0.28%, compared to DXCM's ROE of +0.32%. Regarding short-term risk, CERS is more volatile compared to DXCM. This indicates potentially higher risk in terms of short-term price fluctuations for CERS.Check DXCM's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, STE has a market cap of 24.6B. Regarding current trading prices, CERS is priced at $2.32, while STE trades at $247.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas STE's P/E ratio is 34.92. In terms of profitability, CERS's ROE is -0.28%, compared to STE's ROE of +0.10%. Regarding short-term risk, CERS is more volatile compared to STE. This indicates potentially higher risk in terms of short-term price fluctuations for CERS.Check STE's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, ZBH has a market cap of 19.6B. Regarding current trading prices, CERS is priced at $2.32, while ZBH trades at $98.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas ZBH's P/E ratio is 27.82. In terms of profitability, CERS's ROE is -0.28%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, CERS is more volatile compared to ZBH. This indicates potentially higher risk in terms of short-term price fluctuations for CERS.Check ZBH's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, CERS is priced at $2.32, while ABMD trades at $381.02.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas ABMD's P/E ratio is 65.36. In terms of profitability, CERS's ROE is -0.28%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, CERS is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for CERS.Check ABMD's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, PODD has a market cap of 17B. Regarding current trading prices, CERS is priced at $2.32, while PODD trades at $247.86.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas PODD's P/E ratio is 70.32. In terms of profitability, CERS's ROE is -0.28%, compared to PODD's ROE of +0.17%. Regarding short-term risk, CERS is more volatile compared to PODD. This indicates potentially higher risk in terms of short-term price fluctuations for CERS.Check PODD's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, SNN has a market cap of 15.8B. Regarding current trading prices, CERS is priced at $2.32, while SNN trades at $36.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas SNN's P/E ratio is 32.22. In terms of profitability, CERS's ROE is -0.28%, compared to SNN's ROE of +0.09%. Regarding short-term risk, CERS is more volatile compared to SNN. This indicates potentially higher risk in terms of short-term price fluctuations for CERS.Check SNN's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, ALGN has a market cap of 13.6B. Regarding current trading prices, CERS is priced at $2.32, while ALGN trades at $177.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas ALGN's P/E ratio is 33.63. In terms of profitability, CERS's ROE is -0.28%, compared to ALGN's ROE of +0.10%. Regarding short-term risk, CERS is less volatile compared to ALGN. This indicates potentially lower risk in terms of short-term price fluctuations for CERS.Check ALGN's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, PEN has a market cap of 13.3B. Regarding current trading prices, CERS is priced at $2.32, while PEN trades at $339.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas PEN's P/E ratio is 80.98. In terms of profitability, CERS's ROE is -0.28%, compared to PEN's ROE of +0.13%. Regarding short-term risk, CERS is more volatile compared to PEN. This indicates potentially higher risk in terms of short-term price fluctuations for CERS.Check PEN's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, CERS is priced at $2.32, while SWAV trades at $334.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas SWAV's P/E ratio is 78.76. In terms of profitability, CERS's ROE is -0.28%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, CERS is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for CERS.Check SWAV's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, GMED has a market cap of 12.1B. Regarding current trading prices, CERS is priced at $2.32, while GMED trades at $92.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas GMED's P/E ratio is 29.32. In terms of profitability, CERS's ROE is -0.28%, compared to GMED's ROE of +0.10%. Regarding short-term risk, CERS is more volatile compared to GMED. This indicates potentially higher risk in terms of short-term price fluctuations for CERS.Check GMED's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, BIO has a market cap of 7.3B. Regarding current trading prices, CERS is priced at $2.32, while BIO trades at $269.92.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas BIO's P/E ratio is 9.74. In terms of profitability, CERS's ROE is -0.28%, compared to BIO's ROE of +0.11%. Regarding short-term risk, CERS is more volatile compared to BIO. This indicates potentially higher risk in terms of short-term price fluctuations for CERS.Check BIO's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, BIO-B has a market cap of 7.1B. Regarding current trading prices, CERS is priced at $2.32, while BIO-B trades at $268.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas BIO-B's P/E ratio is 9.40. In terms of profitability, CERS's ROE is -0.28%, compared to BIO-B's ROE of +0.11%. Regarding short-term risk, CERS is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for CERS.Check BIO-B's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, GKOS has a market cap of 6.9B. Regarding current trading prices, CERS is priced at $2.32, while GKOS trades at $119.32.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas GKOS's P/E ratio is -80.81. In terms of profitability, CERS's ROE is -0.28%, compared to GKOS's ROE of -0.25%. Regarding short-term risk, CERS is more volatile compared to GKOS. This indicates potentially higher risk in terms of short-term price fluctuations for CERS.Check GKOS's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, BRKR has a market cap of 5.8B. Regarding current trading prices, CERS is priced at $2.32, while BRKR trades at $39.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas BRKR's P/E ratio is -255.20. In terms of profitability, CERS's ROE is -0.28%, compared to BRKR's ROE of -0.00%. Regarding short-term risk, CERS is less volatile compared to BRKR. This indicates potentially lower risk in terms of short-term price fluctuations for CERS.Check BRKR's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, IRTC has a market cap of 4.9B. Regarding current trading prices, CERS is priced at $2.32, while IRTC trades at $143.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas IRTC's P/E ratio is -93.19. In terms of profitability, CERS's ROE is -0.28%, compared to IRTC's ROE of -0.38%. Regarding short-term risk, CERS is less volatile compared to IRTC. This indicates potentially lower risk in terms of short-term price fluctuations for CERS.Check IRTC's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, CERS is priced at $2.32, while NARI trades at $79.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas NARI's P/E ratio is -59.24. In terms of profitability, CERS's ROE is -0.28%, compared to NARI's ROE of -0.00%. Regarding short-term risk, CERS is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for CERS.Check NARI's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, TMDX has a market cap of 4.6B. Regarding current trading prices, CERS is priced at $2.32, while TMDX trades at $132.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas TMDX's P/E ratio is 53.06. In terms of profitability, CERS's ROE is -0.28%, compared to TMDX's ROE of +0.31%. Regarding short-term risk, CERS is more volatile compared to TMDX. This indicates potentially higher risk in terms of short-term price fluctuations for CERS.Check TMDX's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, LIVN has a market cap of 3.7B. Regarding current trading prices, CERS is priced at $2.32, while LIVN trades at $67.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas LIVN's P/E ratio is -17.19. In terms of profitability, CERS's ROE is -0.28%, compared to LIVN's ROE of -0.19%. Regarding short-term risk, CERS is more volatile compared to LIVN. This indicates potentially higher risk in terms of short-term price fluctuations for CERS.Check LIVN's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, CERS is priced at $2.32, while AXNX trades at $70.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas AXNX's P/E ratio is -709.80. In terms of profitability, CERS's ROE is -0.28%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, CERS is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for CERS.Check AXNX's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, ITGR has a market cap of 3B. Regarding current trading prices, CERS is priced at $2.32, while ITGR trades at $85.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas ITGR's P/E ratio is 34.93. In terms of profitability, CERS's ROE is -0.28%, compared to ITGR's ROE of +0.06%. Regarding short-term risk, CERS is more volatile compared to ITGR. This indicates potentially higher risk in terms of short-term price fluctuations for CERS.Check ITGR's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, ESTA has a market cap of 2.2B. Regarding current trading prices, CERS is priced at $2.32, while ESTA trades at $74.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas ESTA's P/E ratio is -26.76. In terms of profitability, CERS's ROE is -0.28%, compared to ESTA's ROE of -2.54%. Regarding short-term risk, CERS is less volatile compared to ESTA. This indicates potentially lower risk in terms of short-term price fluctuations for CERS.Check ESTA's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, CERS is priced at $2.32, while NUVA trades at $39.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas NUVA's P/E ratio is 75.00. In terms of profitability, CERS's ROE is -0.28%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, CERS is less volatile compared to NUVA. This indicates potentially lower risk in terms of short-term price fluctuations for CERS.Check NUVA's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, PMI has a market cap of 2B. Regarding current trading prices, CERS is priced at $2.32, while PMI trades at $1.16.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas PMI's P/E ratio is -2.84. In terms of profitability, CERS's ROE is -0.28%, compared to PMI's ROE of +1.64%. Regarding short-term risk, CERS is less volatile compared to PMI. This indicates potentially lower risk in terms of short-term price fluctuations for CERS.Check PMI's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, ATEC has a market cap of 1.9B. Regarding current trading prices, CERS is priced at $2.32, while ATEC trades at $12.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas ATEC's P/E ratio is -12.51. In terms of profitability, CERS's ROE is -0.28%, compared to ATEC's ROE of -103.69%. Regarding short-term risk, CERS is more volatile compared to ATEC. This indicates potentially higher risk in terms of short-term price fluctuations for CERS.Check ATEC's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, AORT has a market cap of 1.8B. Regarding current trading prices, CERS is priced at $2.32, while AORT trades at $37.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas AORT's P/E ratio is 182.64. In terms of profitability, CERS's ROE is -0.28%, compared to AORT's ROE of +0.02%. Regarding short-term risk, CERS is more volatile compared to AORT. This indicates potentially higher risk in terms of short-term price fluctuations for CERS.Check AORT's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, UFPT has a market cap of 1.8B. Regarding current trading prices, CERS is priced at $2.32, while UFPT trades at $239.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas UFPT's P/E ratio is 27.15. In terms of profitability, CERS's ROE is -0.28%, compared to UFPT's ROE of +0.18%. Regarding short-term risk, CERS is less volatile compared to UFPT. This indicates potentially lower risk in terms of short-term price fluctuations for CERS.Check UFPT's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, AXGN has a market cap of 1.8B. Regarding current trading prices, CERS is priced at $2.32, while AXGN trades at $35.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas AXGN's P/E ratio is -706.00. In terms of profitability, CERS's ROE is -0.28%, compared to AXGN's ROE of -0.02%. Regarding short-term risk, CERS is more volatile compared to AXGN. This indicates potentially higher risk in terms of short-term price fluctuations for CERS.Check AXGN's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, INSP has a market cap of 1.7B. Regarding current trading prices, CERS is priced at $2.32, while INSP trades at $58.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas INSP's P/E ratio is 12.19. In terms of profitability, CERS's ROE is -0.28%, compared to INSP's ROE of +0.21%. Regarding short-term risk, CERS is more volatile compared to INSP. This indicates potentially higher risk in terms of short-term price fluctuations for CERS.Check INSP's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, TNDM has a market cap of 1.7B. Regarding current trading prices, CERS is priced at $2.32, while TNDM trades at $28.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas TNDM's P/E ratio is -8.11. In terms of profitability, CERS's ROE is -0.28%, compared to TNDM's ROE of -1.20%. Regarding short-term risk, CERS is less volatile compared to TNDM. This indicates potentially lower risk in terms of short-term price fluctuations for CERS.Check TNDM's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, PRCT has a market cap of 1.5B. Regarding current trading prices, CERS is priced at $2.32, while PRCT trades at $27.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas PRCT's P/E ratio is -17.82. In terms of profitability, CERS's ROE is -0.28%, compared to PRCT's ROE of -0.22%. Regarding short-term risk, CERS is less volatile compared to PRCT. This indicates potentially lower risk in terms of short-term price fluctuations for CERS.Check PRCT's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, AHCO has a market cap of 1.4B. Regarding current trading prices, CERS is priced at $2.32, while AHCO trades at $10.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas AHCO's P/E ratio is 18.80. In terms of profitability, CERS's ROE is -0.28%, compared to AHCO's ROE of +0.05%. Regarding short-term risk, CERS is more volatile compared to AHCO. This indicates potentially higher risk in terms of short-term price fluctuations for CERS.Check AHCO's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, CNMD has a market cap of 1.4B. Regarding current trading prices, CERS is priced at $2.32, while CNMD trades at $45.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas CNMD's P/E ratio is 29.90. In terms of profitability, CERS's ROE is -0.28%, compared to CNMD's ROE of +0.05%. Regarding short-term risk, CERS is more volatile compared to CNMD. This indicates potentially higher risk in terms of short-term price fluctuations for CERS.Check CNMD's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, LMRI has a market cap of 1.4B. Regarding current trading prices, CERS is priced at $2.32, while LMRI trades at $15.17.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas LMRI's P/E ratio is -31.63. In terms of profitability, CERS's ROE is -0.28%, compared to LMRI's ROE of -0.52%. Regarding short-term risk, CERS is less volatile compared to LMRI. This indicates potentially lower risk in terms of short-term price fluctuations for CERS.Check LMRI's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, IRMD has a market cap of 1.3B. Regarding current trading prices, CERS is priced at $2.32, while IRMD trades at $100.85.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas IRMD's P/E ratio is 59.18. In terms of profitability, CERS's ROE is -0.28%, compared to IRMD's ROE of +0.24%. Regarding short-term risk, CERS is more volatile compared to IRMD. This indicates potentially higher risk in terms of short-term price fluctuations for CERS.Check IRMD's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, CERS is priced at $2.32, while HSKA trades at $119.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas HSKA's P/E ratio is -62.49. In terms of profitability, CERS's ROE is -0.28%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, CERS is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for CERS.Check HSKA's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, CERS is priced at $2.32, while SILK trades at $27.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas SILK's P/E ratio is -18.96. In terms of profitability, CERS's ROE is -0.28%, compared to SILK's ROE of -0.35%. Regarding short-term risk, CERS is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for CERS.Check SILK's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, CERS is priced at $2.32, while FNA trades at $13.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas FNA's P/E ratio is -19.83. In terms of profitability, CERS's ROE is -0.28%, compared to FNA's ROE of -0.17%. Regarding short-term risk, CERS is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for CERS.Check FNA's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, INMD has a market cap of 964.3M. Regarding current trading prices, CERS is priced at $2.32, while INMD trades at $14.29.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas INMD's P/E ratio is 10.21. In terms of profitability, CERS's ROE is -0.28%, compared to INMD's ROE of +0.15%. Regarding short-term risk, CERS is more volatile compared to INMD. This indicates potentially higher risk in terms of short-term price fluctuations for CERS.Check INMD's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, SSII has a market cap of 959.4M. Regarding current trading prices, CERS is priced at $2.32, while SSII trades at $4.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas SSII's P/E ratio is -82.58. In terms of profitability, CERS's ROE is -0.28%, compared to SSII's ROE of -0.50%. Regarding short-term risk, CERS is less volatile compared to SSII. This indicates potentially lower risk in terms of short-term price fluctuations for CERS.Check SSII's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, IART has a market cap of 951.1M. Regarding current trading prices, CERS is priced at $2.32, while IART trades at $11.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas IART's P/E ratio is -1.89. In terms of profitability, CERS's ROE is -0.28%, compared to IART's ROE of -0.39%. Regarding short-term risk, CERS is less volatile compared to IART. This indicates potentially lower risk in terms of short-term price fluctuations for CERS.Check IART's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, CSII has a market cap of 844M. Regarding current trading prices, CERS is priced at $2.32, while CSII trades at $20.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas CSII's P/E ratio is -20.83. In terms of profitability, CERS's ROE is -0.28%, compared to CSII's ROE of -0.14%. Regarding short-term risk, CERS is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for CERS.Check CSII's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, BFLY has a market cap of 754M. Regarding current trading prices, CERS is priced at $2.32, while BFLY trades at $2.91.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas BFLY's P/E ratio is -9.05. In terms of profitability, CERS's ROE is -0.28%, compared to BFLY's ROE of -0.38%. Regarding short-term risk, CERS is more volatile compared to BFLY. This indicates potentially higher risk in terms of short-term price fluctuations for CERS.Check BFLY's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, CBLL has a market cap of 750.1M. Regarding current trading prices, CERS is priced at $2.32, while CBLL trades at $19.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas CBLL's P/E ratio is -5.51. In terms of profitability, CERS's ROE is -0.28%, compared to CBLL's ROE of -0.30%. Regarding short-term risk, CERS is more volatile compared to CBLL. This indicates potentially higher risk in terms of short-term price fluctuations for CERS.Check CBLL's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, CERS is priced at $2.32, while CRY trades at $17.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas CRY's P/E ratio is 425.71. In terms of profitability, CERS's ROE is -0.28%, compared to CRY's ROE of +0.02%. Regarding short-term risk, CERS is less volatile compared to CRY. This indicates potentially lower risk in terms of short-term price fluctuations for CERS.Check CRY's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, AVNS has a market cap of 718.1M. Regarding current trading prices, CERS is priced at $2.32, while AVNS trades at $15.26.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas AVNS's P/E ratio is -1.52. In terms of profitability, CERS's ROE is -0.28%, compared to AVNS's ROE of -0.58%. Regarding short-term risk, CERS is more volatile compared to AVNS. This indicates potentially higher risk in terms of short-term price fluctuations for CERS.Check AVNS's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, SIBN has a market cap of 671.7M. Regarding current trading prices, CERS is priced at $2.32, while SIBN trades at $15.78.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas SIBN's P/E ratio is -30.35. In terms of profitability, CERS's ROE is -0.28%, compared to SIBN's ROE of -0.13%. Regarding short-term risk, CERS is less volatile compared to SIBN. This indicates potentially lower risk in terms of short-term price fluctuations for CERS.Check SIBN's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, TCMD has a market cap of 641.5M. Regarding current trading prices, CERS is priced at $2.32, while TCMD trades at $28.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas TCMD's P/E ratio is 44.18. In terms of profitability, CERS's ROE is -0.28%, compared to TCMD's ROE of +0.09%. Regarding short-term risk, CERS is less volatile compared to TCMD. This indicates potentially lower risk in terms of short-term price fluctuations for CERS.Check TCMD's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, CERS is priced at $2.32, while SRDX trades at $42.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas SRDX's P/E ratio is -34.66. In terms of profitability, CERS's ROE is -0.28%, compared to SRDX's ROE of -0.16%. Regarding short-term risk, CERS is more volatile compared to SRDX. This indicates potentially higher risk in terms of short-term price fluctuations for CERS.Check SRDX's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, CERS is priced at $2.32, while APEN trades at $10.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas APEN's P/E ratio is -9.43. In terms of profitability, CERS's ROE is -0.28%, compared to APEN's ROE of -0.85%. Regarding short-term risk, CERS is more volatile compared to APEN. This indicates potentially higher risk in terms of short-term price fluctuations for CERS.Check APEN's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, BVS has a market cap of 574.7M. Regarding current trading prices, CERS is priced at $2.32, while BVS trades at $8.64.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas BVS's P/E ratio is 53.63. In terms of profitability, CERS's ROE is -0.28%, compared to BVS's ROE of +0.05%. Regarding short-term risk, CERS is more volatile compared to BVS. This indicates potentially higher risk in terms of short-term price fluctuations for CERS.Check BVS's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, VREX has a market cap of 569.7M. Regarding current trading prices, CERS is priced at $2.32, while VREX trades at $13.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas VREX's P/E ratio is -8.29. In terms of profitability, CERS's ROE is -0.28%, compared to VREX's ROE of -0.14%. Regarding short-term risk, CERS is more volatile compared to VREX. This indicates potentially higher risk in terms of short-term price fluctuations for CERS.Check VREX's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, CTKB has a market cap of 566.4M. Regarding current trading prices, CERS is priced at $2.32, while CTKB trades at $4.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas CTKB's P/E ratio is -40.27. In terms of profitability, CERS's ROE is -0.28%, compared to CTKB's ROE of -0.03%. Regarding short-term risk, CERS is less volatile compared to CTKB. This indicates potentially lower risk in terms of short-term price fluctuations for CERS.Check CTKB's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, OFIX has a market cap of 549.2M. Regarding current trading prices, CERS is priced at $2.32, while OFIX trades at $13.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas OFIX's P/E ratio is -4.58. In terms of profitability, CERS's ROE is -0.28%, compared to OFIX's ROE of -0.26%. Regarding short-term risk, CERS is less volatile compared to OFIX. This indicates potentially lower risk in terms of short-term price fluctuations for CERS.Check OFIX's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, CERS is priced at $2.32, while ZIMV trades at $18.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, CERS's ROE is -0.28%, compared to ZIMV's ROE of -0.05%. Regarding short-term risk, CERS is more volatile compared to ZIMV. This indicates potentially higher risk in terms of short-term price fluctuations for CERS.Check ZIMV's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, BWAY has a market cap of 487.3M. Regarding current trading prices, CERS is priced at $2.32, while BWAY trades at $23.72.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas BWAY's P/E ratio is 83.17. In terms of profitability, CERS's ROE is -0.28%, compared to BWAY's ROE of +0.09%. Regarding short-term risk, CERS is less volatile compared to BWAY. This indicates potentially lower risk in terms of short-term price fluctuations for CERS.Check BWAY's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, PACB has a market cap of 486.1M. Regarding current trading prices, CERS is priced at $2.32, while PACB trades at $1.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas PACB's P/E ratio is -0.88. In terms of profitability, CERS's ROE is -0.28%, compared to PACB's ROE of -11.23%. Regarding short-term risk, CERS is less volatile compared to PACB. This indicates potentially lower risk in terms of short-term price fluctuations for CERS.Check PACB's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, NPCE has a market cap of 477.6M. Regarding current trading prices, CERS is priced at $2.32, while NPCE trades at $14.53.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas NPCE's P/E ratio is -19.12. In terms of profitability, CERS's ROE is -0.28%, compared to NPCE's ROE of -1.37%. Regarding short-term risk, CERS is more volatile compared to NPCE. This indicates potentially higher risk in terms of short-term price fluctuations for CERS.Check NPCE's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, LAB has a market cap of 434.6M. Regarding current trading prices, CERS is priced at $2.32, while LAB trades at $1.12.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas LAB's P/E ratio is -2.90. In terms of profitability, CERS's ROE is -0.28%, compared to LAB's ROE of -0.29%. Regarding short-term risk, CERS is more volatile compared to LAB. This indicates potentially higher risk in terms of short-term price fluctuations for CERS.Check LAB's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, KIDS has a market cap of 425.3M. Regarding current trading prices, CERS is priced at $2.32, while KIDS trades at $16.47.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas KIDS's P/E ratio is -8.65. In terms of profitability, CERS's ROE is -0.28%, compared to KIDS's ROE of -0.13%. Regarding short-term risk, CERS is less volatile compared to KIDS. This indicates potentially lower risk in terms of short-term price fluctuations for CERS.Check KIDS's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, CATX has a market cap of 421.5M. Regarding current trading prices, CERS is priced at $2.32, while CATX trades at $5.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas CATX's P/E ratio is -3.75. In terms of profitability, CERS's ROE is -0.28%, compared to CATX's ROE of -0.39%. Regarding short-term risk, CERS is less volatile compared to CATX. This indicates potentially lower risk in terms of short-term price fluctuations for CERS.Check CATX's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, CLPT has a market cap of 420.9M. Regarding current trading prices, CERS is priced at $2.32, while CLPT trades at $14.44.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas CLPT's P/E ratio is -17.05. In terms of profitability, CERS's ROE is -0.28%, compared to CLPT's ROE of -1.14%. Regarding short-term risk, CERS is less volatile compared to CLPT. This indicates potentially lower risk in terms of short-term price fluctuations for CERS.Check CLPT's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, RXST has a market cap of 354.8M. Regarding current trading prices, CERS is priced at $2.32, while RXST trades at $8.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas RXST's P/E ratio is -9.81. In terms of profitability, CERS's ROE is -0.28%, compared to RXST's ROE of -0.13%. Regarding short-term risk, CERS is more volatile compared to RXST. This indicates potentially higher risk in terms of short-term price fluctuations for CERS.Check RXST's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, DCTH has a market cap of 339.4M. Regarding current trading prices, CERS is priced at $2.32, while DCTH trades at $9.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas DCTH's P/E ratio is 326.00. In terms of profitability, CERS's ROE is -0.28%, compared to DCTH's ROE of +0.01%. Regarding short-term risk, CERS is less volatile compared to DCTH. This indicates potentially lower risk in terms of short-term price fluctuations for CERS.Check DCTH's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, SENS has a market cap of 333.4M. Regarding current trading prices, CERS is priced at $2.32, while SENS trades at $8.15.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas SENS's P/E ratio is -5.30. In terms of profitability, CERS's ROE is -0.28%, compared to SENS's ROE of -1.35%. Regarding short-term risk, CERS is less volatile compared to SENS. This indicates potentially lower risk in terms of short-term price fluctuations for CERS.Check SENS's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, VMD has a market cap of 319.6M. Regarding current trading prices, CERS is priced at $2.32, while VMD trades at $8.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas VMD's P/E ratio is 24.24. In terms of profitability, CERS's ROE is -0.28%, compared to VMD's ROE of +0.10%. Regarding short-term risk, CERS is more volatile compared to VMD. This indicates potentially higher risk in terms of short-term price fluctuations for CERS.Check VMD's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, CERS is priced at $2.32, while SMLR trades at $20.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas SMLR's P/E ratio is 3.92. In terms of profitability, CERS's ROE is -0.28%, compared to SMLR's ROE of +0.16%. Regarding short-term risk, CERS is more volatile compared to SMLR. This indicates potentially higher risk in terms of short-term price fluctuations for CERS.Check SMLR's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, SGHT has a market cap of 285.5M. Regarding current trading prices, CERS is priced at $2.32, while SGHT trades at $5.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas SGHT's P/E ratio is -6.00. In terms of profitability, CERS's ROE is -0.28%, compared to SGHT's ROE of -0.62%. Regarding short-term risk, CERS is less volatile compared to SGHT. This indicates potentially lower risk in terms of short-term price fluctuations for CERS.Check SGHT's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, QTRX has a market cap of 269.1M. Regarding current trading prices, CERS is priced at $2.32, while QTRX trades at $5.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas QTRX's P/E ratio is -2.46. In terms of profitability, CERS's ROE is -0.28%, compared to QTRX's ROE of -0.31%. Regarding short-term risk, CERS is less volatile compared to QTRX. This indicates potentially lower risk in terms of short-term price fluctuations for CERS.Check QTRX's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, CERS is priced at $2.32, while MGRM trades at $6.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas MGRM's P/E ratio is -11.11. In terms of profitability, CERS's ROE is -0.28%, compared to MGRM's ROE of -1.37%. Regarding short-term risk, CERS is more volatile compared to MGRM. This indicates potentially higher risk in terms of short-term price fluctuations for CERS.Check MGRM's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, MASS has a market cap of 241.4M. Regarding current trading prices, CERS is priced at $2.32, while MASS trades at $6.41.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas MASS's P/E ratio is -3.22. In terms of profitability, CERS's ROE is -0.28%, compared to MASS's ROE of -0.03%. Regarding short-term risk, CERS is less volatile compared to MASS. This indicates potentially lower risk in terms of short-term price fluctuations for CERS.Check MASS's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, CERS is priced at $2.32, while NVRO trades at $5.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas NVRO's P/E ratio is -1.91. In terms of profitability, CERS's ROE is -0.28%, compared to NVRO's ROE of -0.27%. Regarding short-term risk, CERS is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for CERS.Check NVRO's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, PROF has a market cap of 210.2M. Regarding current trading prices, CERS is priced at $2.32, while PROF trades at $7.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas PROF's P/E ratio is -5.27. In terms of profitability, CERS's ROE is -0.28%, compared to PROF's ROE of -0.92%. Regarding short-term risk, CERS is more volatile compared to PROF. This indicates potentially higher risk in terms of short-term price fluctuations for CERS.Check PROF's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, EYES has a market cap of 210M. Regarding current trading prices, CERS is priced at $2.32, while EYES trades at $4.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas EYES's P/E ratio is N/A. In terms of profitability, CERS's ROE is -0.28%, compared to EYES's ROE of -4.16%. Regarding short-term risk, CERS is less volatile compared to EYES. This indicates potentially lower risk in terms of short-term price fluctuations for CERS.Check EYES's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, SNWV has a market cap of 208M. Regarding current trading prices, CERS is priced at $2.32, while SNWV trades at $24.21.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas SNWV's P/E ratio is -33.22. In terms of profitability, CERS's ROE is -0.28%, compared to SNWV's ROE of +0.59%. Regarding short-term risk, CERS is less volatile compared to SNWV. This indicates potentially lower risk in terms of short-term price fluctuations for CERS.Check SNWV's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, ELMD has a market cap of 203.2M. Regarding current trading prices, CERS is priced at $2.32, while ELMD trades at $25.19.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas ELMD's P/E ratio is 23.65. In terms of profitability, CERS's ROE is -0.28%, compared to ELMD's ROE of +0.20%. Regarding short-term risk, CERS is less volatile compared to ELMD. This indicates potentially lower risk in terms of short-term price fluctuations for CERS.Check ELMD's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, CERS is priced at $2.32, while BSGM trades at $6.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas BSGM's P/E ratio is -5.81. In terms of profitability, CERS's ROE is -0.28%, compared to BSGM's ROE of +17.60%. Regarding short-term risk, CERS is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for CERS.Check BSGM's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, AVR has a market cap of 186.9M. Regarding current trading prices, CERS is priced at $2.32, while AVR trades at $6.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas AVR's P/E ratio is -2.18. In terms of profitability, CERS's ROE is -0.28%, compared to AVR's ROE of -2.51%. Regarding short-term risk, CERS is less volatile compared to AVR. This indicates potentially lower risk in terms of short-term price fluctuations for CERS.Check AVR's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, OWLT has a market cap of 181.5M. Regarding current trading prices, CERS is priced at $2.32, while OWLT trades at $10.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas OWLT's P/E ratio is -4.04. In terms of profitability, CERS's ROE is -0.28%, compared to OWLT's ROE of +1.27%. Regarding short-term risk, CERS is less volatile compared to OWLT. This indicates potentially lower risk in terms of short-term price fluctuations for CERS.Check OWLT's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, TLSI has a market cap of 180.1M. Regarding current trading prices, CERS is priced at $2.32, while TLSI trades at $5.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas TLSI's P/E ratio is -2.57. In terms of profitability, CERS's ROE is -0.28%, compared to TLSI's ROE of +1.49%. Regarding short-term risk, CERS is less volatile compared to TLSI. This indicates potentially lower risk in terms of short-term price fluctuations for CERS.Check TLSI's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, CERS is priced at $2.32, while MDGS trades at $2.36.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas MDGS's P/E ratio is -0.27. In terms of profitability, CERS's ROE is -0.28%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, CERS is less volatile compared to MDGS. This indicates potentially lower risk in terms of short-term price fluctuations for CERS.Check MDGS's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, EDAP has a market cap of 176.1M. Regarding current trading prices, CERS is priced at $2.32, while EDAP trades at $4.43.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas EDAP's P/E ratio is -8.26. In terms of profitability, CERS's ROE is -0.28%, compared to EDAP's ROE of -0.62%. Regarding short-term risk, CERS is less volatile compared to EDAP. This indicates potentially lower risk in terms of short-term price fluctuations for CERS.Check EDAP's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, RPID has a market cap of 172.4M. Regarding current trading prices, CERS is priced at $2.32, while RPID trades at $3.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas RPID's P/E ratio is -3.89. In terms of profitability, CERS's ROE is -0.28%, compared to RPID's ROE of -0.74%. Regarding short-term risk, CERS is less volatile compared to RPID. This indicates potentially lower risk in terms of short-term price fluctuations for CERS.Check RPID's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, CVRX has a market cap of 160.8M. Regarding current trading prices, CERS is priced at $2.32, while CVRX trades at $6.84.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas CVRX's P/E ratio is -3.00. In terms of profitability, CERS's ROE is -0.28%, compared to CVRX's ROE of -0.99%. Regarding short-term risk, CERS is less volatile compared to CVRX. This indicates potentially lower risk in terms of short-term price fluctuations for CERS.Check CVRX's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, QIPT has a market cap of 160.5M. Regarding current trading prices, CERS is priced at $2.32, while QIPT trades at $3.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas QIPT's P/E ratio is -15.70. In terms of profitability, CERS's ROE is -0.28%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, CERS is more volatile compared to QIPT. This indicates potentially higher risk in terms of short-term price fluctuations for CERS.Check QIPT's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, INGN has a market cap of 157.2M. Regarding current trading prices, CERS is priced at $2.32, while INGN trades at $5.67.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas INGN's P/E ratio is -5.79. In terms of profitability, CERS's ROE is -0.28%, compared to INGN's ROE of -0.13%. Regarding short-term risk, CERS is more volatile compared to INGN. This indicates potentially higher risk in terms of short-term price fluctuations for CERS.Check INGN's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, APYX has a market cap of 155.1M. Regarding current trading prices, CERS is priced at $2.32, while APYX trades at $3.54.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas APYX's P/E ratio is -10.50. In terms of profitability, CERS's ROE is -0.28%, compared to APYX's ROE of -1.54%. Regarding short-term risk, CERS is less volatile compared to APYX. This indicates potentially lower risk in terms of short-term price fluctuations for CERS.Check APYX's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, NNOX has a market cap of 154.9M. Regarding current trading prices, CERS is priced at $2.32, while NNOX trades at $2.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas NNOX's P/E ratio is -2.76. In terms of profitability, CERS's ROE is -0.28%, compared to NNOX's ROE of -0.32%. Regarding short-term risk, CERS is less volatile compared to NNOX. This indicates potentially lower risk in terms of short-term price fluctuations for CERS.Check NNOX's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, ANIK has a market cap of 153.3M. Regarding current trading prices, CERS is priced at $2.32, while ANIK trades at $10.89.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas ANIK's P/E ratio is -10.74. In terms of profitability, CERS's ROE is -0.28%, compared to ANIK's ROE of -0.22%. Regarding short-term risk, CERS is more volatile compared to ANIK. This indicates potentially higher risk in terms of short-term price fluctuations for CERS.Check ANIK's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, QTI has a market cap of 149.5M. Regarding current trading prices, CERS is priced at $2.32, while QTI trades at $5.50.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas QTI's P/E ratio is -2.28. In terms of profitability, CERS's ROE is -0.28%, compared to QTI's ROE of +1.72%. Regarding short-term risk, CERS is less volatile compared to QTI. This indicates potentially lower risk in terms of short-term price fluctuations for CERS.Check QTI's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, LNSR has a market cap of 139.6M. Regarding current trading prices, CERS is priced at $2.32, while LNSR trades at $11.73.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas LNSR's P/E ratio is -2.68. In terms of profitability, CERS's ROE is -0.28%, compared to LNSR's ROE of +5.33%. Regarding short-term risk, CERS is more volatile compared to LNSR. This indicates potentially higher risk in terms of short-term price fluctuations for CERS.Check LNSR's competition here

CERS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, CERS stands at 462.9M. In comparison, LUCD has a market cap of 138.4M. Regarding current trading prices, CERS is priced at $2.32, while LUCD trades at $1.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

CERS currently has a P/E ratio of -30.12, whereas LUCD's P/E ratio is -1.77. In terms of profitability, CERS's ROE is -0.28%, compared to LUCD's ROE of -6.32%. Regarding short-term risk, CERS is less volatile compared to LUCD. This indicates potentially lower risk in terms of short-term price fluctuations for CERS.Check LUCD's competition here